Mineralocorticoid Receptor Antagonism Attenuates Cardiac Hypertrophy and Prevents Oxidative Stress in Uremic Rats

Chronic renal failure causes left ventricular hypertrophy, but the molecular mechanisms involved remain unknown. We, therefore, investigated whether the mineralocorticoid receptor is implicated in the cardiac hypertrophy observed in uremic rats and whether mineralocorticoid receptor blockade could b...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Hypertension (Dallas, Tex. 1979) Tex. 1979), 2008-08, Vol.52 (2), p.295-300
Hauptverfasser: Michea, Luis, Villagrán, Andrea, Urzúa, Alvaro, Kuntsmann, Sonia, Venegas, Patricio, Carrasco, Loreto, Gonzalez, Magdalena, Marusic, Elisa T
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 300
container_issue 2
container_start_page 295
container_title Hypertension (Dallas, Tex. 1979)
container_volume 52
creator Michea, Luis
Villagrán, Andrea
Urzúa, Alvaro
Kuntsmann, Sonia
Venegas, Patricio
Carrasco, Loreto
Gonzalez, Magdalena
Marusic, Elisa T
description Chronic renal failure causes left ventricular hypertrophy, but the molecular mechanisms involved remain unknown. We, therefore, investigated whether the mineralocorticoid receptor is implicated in the cardiac hypertrophy observed in uremic rats and whether mineralocorticoid receptor blockade could be protective in chronic renal failure. Experimental groups werecontrol rats, uremic rats (NPX) with 5/6 nephrectomy (5 weeks), and NPX rats fed with spironolactone for 5 weeks. Systolic blood pressure was increased in both NPX rats and NPX rats fed with spironolactone for 5 weeks. Echocardiography revealed concentric left ventricular hypertrophy in uremia, which was attenuated by spironolactone. Enlarged cardiomyocyte size was observed in both left and right ventricles of NPX rats, an effect that was prevented by spironolactone. Mineralocorticoid receptor antagonism attenuated the increase of ventricular brain natriuretic peptide mRNA levels induced by nephrectomy. Left ventricular gene expressions of aldosterone synthase, mineralocorticoid receptor, and hydroxysteroid dehydrogenase type 2 were the same in the 3 groups, whereas gene expression of the glucocorticoid receptor was significantly diminished in chronic renal failure rats. No significant differences in cardiac aldosterone were observed between control rats and NPX rats, although NPX rats fed with spironolactone for 5 weeks showed increased plasma aldosterone levels. However, a significant increase in serum and glucocorticoid-inducible kinase-1 mRNA expression and protein was present in the NPX group; spironolactone treatment significantly reduced serum and glucocorticoid-inducible kinase-1 mRNA and protein in the left ventricle. Uremic rats exhibited a significant increase of superoxide production and reduced nicotinamide-adenine dinucleotide phosphate oxidase subunits expression (NOX-2, NOX-4, and p47) in the left ventricle, which was prevented by the mineralocorticoid receptor antagonist. Our findings provide evidence of the beneficial effects of spironolactone in cardiac hypertrophy and cardiac oxidative stress in chronic renal failure.
doi_str_mv 10.1161/HYPERTENSIONAHA.107.109645
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69355037</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>69355037</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5214-bc97bbb23064f263c693940e25577ec9ce872b59b4e33d85ba8634cf40512a413</originalsourceid><addsrcrecordid>eNpdkF9rFDEUxYModq1-BQk--DY1f2cmvg3L1i3Ubtm2oE8hk7nrRmcm0yTTut_eyC4I3svlwuWcc-GH0AdKLigt6af199vV9n51c3e1uWnWzQUlVR5VCvkCLahkohCy5C_RglAlCkXptzP0JsafhFAhRPUandFaKipkvUCPX90IwfTe-pCc9a7DW7AwJR9wMybzw48uDrhJCcbZJIh4aULnjMXrwwQhBT_tD9iMHb4N8ARjinjz23UmuSfAdylAjNiN-CHA4CzemhTfolc700d4d9rn6OFydb9cF9ebL1fL5rqwklFRtFZVbdsyTkqxYyW3peJKEGBSVhVYZaGuWCtVK4DzrpatqUsu7E4QSZkRlJ-jj8fcKfjHGWLSg4sW-t6M4Oeoc56UhFdZ-PkotMHHGGCnp-AGEw6aEv0XuP4PeL5X-gg8m9-fvsztAN0_64lwFoij4Nn3CUL81c_PEPQeTJ_2muQSrKwLRkidm5AiDxP8D3taj6M</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69355037</pqid></control><display><type>article</type><title>Mineralocorticoid Receptor Antagonism Attenuates Cardiac Hypertrophy and Prevents Oxidative Stress in Uremic Rats</title><source>MEDLINE</source><source>American Heart Association Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Journals@Ovid Complete</source><creator>Michea, Luis ; Villagrán, Andrea ; Urzúa, Alvaro ; Kuntsmann, Sonia ; Venegas, Patricio ; Carrasco, Loreto ; Gonzalez, Magdalena ; Marusic, Elisa T</creator><creatorcontrib>Michea, Luis ; Villagrán, Andrea ; Urzúa, Alvaro ; Kuntsmann, Sonia ; Venegas, Patricio ; Carrasco, Loreto ; Gonzalez, Magdalena ; Marusic, Elisa T</creatorcontrib><description>Chronic renal failure causes left ventricular hypertrophy, but the molecular mechanisms involved remain unknown. We, therefore, investigated whether the mineralocorticoid receptor is implicated in the cardiac hypertrophy observed in uremic rats and whether mineralocorticoid receptor blockade could be protective in chronic renal failure. Experimental groups werecontrol rats, uremic rats (NPX) with 5/6 nephrectomy (5 weeks), and NPX rats fed with spironolactone for 5 weeks. Systolic blood pressure was increased in both NPX rats and NPX rats fed with spironolactone for 5 weeks. Echocardiography revealed concentric left ventricular hypertrophy in uremia, which was attenuated by spironolactone. Enlarged cardiomyocyte size was observed in both left and right ventricles of NPX rats, an effect that was prevented by spironolactone. Mineralocorticoid receptor antagonism attenuated the increase of ventricular brain natriuretic peptide mRNA levels induced by nephrectomy. Left ventricular gene expressions of aldosterone synthase, mineralocorticoid receptor, and hydroxysteroid dehydrogenase type 2 were the same in the 3 groups, whereas gene expression of the glucocorticoid receptor was significantly diminished in chronic renal failure rats. No significant differences in cardiac aldosterone were observed between control rats and NPX rats, although NPX rats fed with spironolactone for 5 weeks showed increased plasma aldosterone levels. However, a significant increase in serum and glucocorticoid-inducible kinase-1 mRNA expression and protein was present in the NPX group; spironolactone treatment significantly reduced serum and glucocorticoid-inducible kinase-1 mRNA and protein in the left ventricle. Uremic rats exhibited a significant increase of superoxide production and reduced nicotinamide-adenine dinucleotide phosphate oxidase subunits expression (NOX-2, NOX-4, and p47) in the left ventricle, which was prevented by the mineralocorticoid receptor antagonist. Our findings provide evidence of the beneficial effects of spironolactone in cardiac hypertrophy and cardiac oxidative stress in chronic renal failure.</description><identifier>ISSN: 0194-911X</identifier><identifier>EISSN: 1524-4563</identifier><identifier>DOI: 10.1161/HYPERTENSIONAHA.107.109645</identifier><identifier>PMID: 18591458</identifier><language>eng</language><publisher>United States: American Heart Association, Inc</publisher><subject>Analysis of Variance ; Animals ; Biomarkers - analysis ; Blotting, Western ; Cardiomegaly - prevention &amp; control ; Disease Models, Animal ; Immediate-Early Proteins - genetics ; Immediate-Early Proteins - metabolism ; Male ; Mineralocorticoid Receptor Antagonists - pharmacology ; Nephrectomy ; Oxidative Stress - drug effects ; Probability ; Protein-Serine-Threonine Kinases - genetics ; Protein-Serine-Threonine Kinases - metabolism ; Random Allocation ; Rats ; Rats, Sprague-Dawley ; Receptors, Mineralocorticoid - metabolism ; Reverse Transcriptase Polymerase Chain Reaction ; RNA, Messenger - analysis ; Spironolactone - pharmacology ; Uremia - physiopathology ; Urinalysis</subject><ispartof>Hypertension (Dallas, Tex. 1979), 2008-08, Vol.52 (2), p.295-300</ispartof><rights>2008 American Heart Association, Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5214-bc97bbb23064f263c693940e25577ec9ce872b59b4e33d85ba8634cf40512a413</citedby><cites>FETCH-LOGICAL-c5214-bc97bbb23064f263c693940e25577ec9ce872b59b4e33d85ba8634cf40512a413</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,782,786,3689,27931,27932</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18591458$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Michea, Luis</creatorcontrib><creatorcontrib>Villagrán, Andrea</creatorcontrib><creatorcontrib>Urzúa, Alvaro</creatorcontrib><creatorcontrib>Kuntsmann, Sonia</creatorcontrib><creatorcontrib>Venegas, Patricio</creatorcontrib><creatorcontrib>Carrasco, Loreto</creatorcontrib><creatorcontrib>Gonzalez, Magdalena</creatorcontrib><creatorcontrib>Marusic, Elisa T</creatorcontrib><title>Mineralocorticoid Receptor Antagonism Attenuates Cardiac Hypertrophy and Prevents Oxidative Stress in Uremic Rats</title><title>Hypertension (Dallas, Tex. 1979)</title><addtitle>Hypertension</addtitle><description>Chronic renal failure causes left ventricular hypertrophy, but the molecular mechanisms involved remain unknown. We, therefore, investigated whether the mineralocorticoid receptor is implicated in the cardiac hypertrophy observed in uremic rats and whether mineralocorticoid receptor blockade could be protective in chronic renal failure. Experimental groups werecontrol rats, uremic rats (NPX) with 5/6 nephrectomy (5 weeks), and NPX rats fed with spironolactone for 5 weeks. Systolic blood pressure was increased in both NPX rats and NPX rats fed with spironolactone for 5 weeks. Echocardiography revealed concentric left ventricular hypertrophy in uremia, which was attenuated by spironolactone. Enlarged cardiomyocyte size was observed in both left and right ventricles of NPX rats, an effect that was prevented by spironolactone. Mineralocorticoid receptor antagonism attenuated the increase of ventricular brain natriuretic peptide mRNA levels induced by nephrectomy. Left ventricular gene expressions of aldosterone synthase, mineralocorticoid receptor, and hydroxysteroid dehydrogenase type 2 were the same in the 3 groups, whereas gene expression of the glucocorticoid receptor was significantly diminished in chronic renal failure rats. No significant differences in cardiac aldosterone were observed between control rats and NPX rats, although NPX rats fed with spironolactone for 5 weeks showed increased plasma aldosterone levels. However, a significant increase in serum and glucocorticoid-inducible kinase-1 mRNA expression and protein was present in the NPX group; spironolactone treatment significantly reduced serum and glucocorticoid-inducible kinase-1 mRNA and protein in the left ventricle. Uremic rats exhibited a significant increase of superoxide production and reduced nicotinamide-adenine dinucleotide phosphate oxidase subunits expression (NOX-2, NOX-4, and p47) in the left ventricle, which was prevented by the mineralocorticoid receptor antagonist. Our findings provide evidence of the beneficial effects of spironolactone in cardiac hypertrophy and cardiac oxidative stress in chronic renal failure.</description><subject>Analysis of Variance</subject><subject>Animals</subject><subject>Biomarkers - analysis</subject><subject>Blotting, Western</subject><subject>Cardiomegaly - prevention &amp; control</subject><subject>Disease Models, Animal</subject><subject>Immediate-Early Proteins - genetics</subject><subject>Immediate-Early Proteins - metabolism</subject><subject>Male</subject><subject>Mineralocorticoid Receptor Antagonists - pharmacology</subject><subject>Nephrectomy</subject><subject>Oxidative Stress - drug effects</subject><subject>Probability</subject><subject>Protein-Serine-Threonine Kinases - genetics</subject><subject>Protein-Serine-Threonine Kinases - metabolism</subject><subject>Random Allocation</subject><subject>Rats</subject><subject>Rats, Sprague-Dawley</subject><subject>Receptors, Mineralocorticoid - metabolism</subject><subject>Reverse Transcriptase Polymerase Chain Reaction</subject><subject>RNA, Messenger - analysis</subject><subject>Spironolactone - pharmacology</subject><subject>Uremia - physiopathology</subject><subject>Urinalysis</subject><issn>0194-911X</issn><issn>1524-4563</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkF9rFDEUxYModq1-BQk--DY1f2cmvg3L1i3Ubtm2oE8hk7nrRmcm0yTTut_eyC4I3svlwuWcc-GH0AdKLigt6af199vV9n51c3e1uWnWzQUlVR5VCvkCLahkohCy5C_RglAlCkXptzP0JsafhFAhRPUandFaKipkvUCPX90IwfTe-pCc9a7DW7AwJR9wMybzw48uDrhJCcbZJIh4aULnjMXrwwQhBT_tD9iMHb4N8ARjinjz23UmuSfAdylAjNiN-CHA4CzemhTfolc700d4d9rn6OFydb9cF9ebL1fL5rqwklFRtFZVbdsyTkqxYyW3peJKEGBSVhVYZaGuWCtVK4DzrpatqUsu7E4QSZkRlJ-jj8fcKfjHGWLSg4sW-t6M4Oeoc56UhFdZ-PkotMHHGGCnp-AGEw6aEv0XuP4PeL5X-gg8m9-fvsztAN0_64lwFoij4Nn3CUL81c_PEPQeTJ_2muQSrKwLRkidm5AiDxP8D3taj6M</recordid><startdate>200808</startdate><enddate>200808</enddate><creator>Michea, Luis</creator><creator>Villagrán, Andrea</creator><creator>Urzúa, Alvaro</creator><creator>Kuntsmann, Sonia</creator><creator>Venegas, Patricio</creator><creator>Carrasco, Loreto</creator><creator>Gonzalez, Magdalena</creator><creator>Marusic, Elisa T</creator><general>American Heart Association, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200808</creationdate><title>Mineralocorticoid Receptor Antagonism Attenuates Cardiac Hypertrophy and Prevents Oxidative Stress in Uremic Rats</title><author>Michea, Luis ; Villagrán, Andrea ; Urzúa, Alvaro ; Kuntsmann, Sonia ; Venegas, Patricio ; Carrasco, Loreto ; Gonzalez, Magdalena ; Marusic, Elisa T</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5214-bc97bbb23064f263c693940e25577ec9ce872b59b4e33d85ba8634cf40512a413</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Analysis of Variance</topic><topic>Animals</topic><topic>Biomarkers - analysis</topic><topic>Blotting, Western</topic><topic>Cardiomegaly - prevention &amp; control</topic><topic>Disease Models, Animal</topic><topic>Immediate-Early Proteins - genetics</topic><topic>Immediate-Early Proteins - metabolism</topic><topic>Male</topic><topic>Mineralocorticoid Receptor Antagonists - pharmacology</topic><topic>Nephrectomy</topic><topic>Oxidative Stress - drug effects</topic><topic>Probability</topic><topic>Protein-Serine-Threonine Kinases - genetics</topic><topic>Protein-Serine-Threonine Kinases - metabolism</topic><topic>Random Allocation</topic><topic>Rats</topic><topic>Rats, Sprague-Dawley</topic><topic>Receptors, Mineralocorticoid - metabolism</topic><topic>Reverse Transcriptase Polymerase Chain Reaction</topic><topic>RNA, Messenger - analysis</topic><topic>Spironolactone - pharmacology</topic><topic>Uremia - physiopathology</topic><topic>Urinalysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Michea, Luis</creatorcontrib><creatorcontrib>Villagrán, Andrea</creatorcontrib><creatorcontrib>Urzúa, Alvaro</creatorcontrib><creatorcontrib>Kuntsmann, Sonia</creatorcontrib><creatorcontrib>Venegas, Patricio</creatorcontrib><creatorcontrib>Carrasco, Loreto</creatorcontrib><creatorcontrib>Gonzalez, Magdalena</creatorcontrib><creatorcontrib>Marusic, Elisa T</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Hypertension (Dallas, Tex. 1979)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Michea, Luis</au><au>Villagrán, Andrea</au><au>Urzúa, Alvaro</au><au>Kuntsmann, Sonia</au><au>Venegas, Patricio</au><au>Carrasco, Loreto</au><au>Gonzalez, Magdalena</au><au>Marusic, Elisa T</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Mineralocorticoid Receptor Antagonism Attenuates Cardiac Hypertrophy and Prevents Oxidative Stress in Uremic Rats</atitle><jtitle>Hypertension (Dallas, Tex. 1979)</jtitle><addtitle>Hypertension</addtitle><date>2008-08</date><risdate>2008</risdate><volume>52</volume><issue>2</issue><spage>295</spage><epage>300</epage><pages>295-300</pages><issn>0194-911X</issn><eissn>1524-4563</eissn><abstract>Chronic renal failure causes left ventricular hypertrophy, but the molecular mechanisms involved remain unknown. We, therefore, investigated whether the mineralocorticoid receptor is implicated in the cardiac hypertrophy observed in uremic rats and whether mineralocorticoid receptor blockade could be protective in chronic renal failure. Experimental groups werecontrol rats, uremic rats (NPX) with 5/6 nephrectomy (5 weeks), and NPX rats fed with spironolactone for 5 weeks. Systolic blood pressure was increased in both NPX rats and NPX rats fed with spironolactone for 5 weeks. Echocardiography revealed concentric left ventricular hypertrophy in uremia, which was attenuated by spironolactone. Enlarged cardiomyocyte size was observed in both left and right ventricles of NPX rats, an effect that was prevented by spironolactone. Mineralocorticoid receptor antagonism attenuated the increase of ventricular brain natriuretic peptide mRNA levels induced by nephrectomy. Left ventricular gene expressions of aldosterone synthase, mineralocorticoid receptor, and hydroxysteroid dehydrogenase type 2 were the same in the 3 groups, whereas gene expression of the glucocorticoid receptor was significantly diminished in chronic renal failure rats. No significant differences in cardiac aldosterone were observed between control rats and NPX rats, although NPX rats fed with spironolactone for 5 weeks showed increased plasma aldosterone levels. However, a significant increase in serum and glucocorticoid-inducible kinase-1 mRNA expression and protein was present in the NPX group; spironolactone treatment significantly reduced serum and glucocorticoid-inducible kinase-1 mRNA and protein in the left ventricle. Uremic rats exhibited a significant increase of superoxide production and reduced nicotinamide-adenine dinucleotide phosphate oxidase subunits expression (NOX-2, NOX-4, and p47) in the left ventricle, which was prevented by the mineralocorticoid receptor antagonist. Our findings provide evidence of the beneficial effects of spironolactone in cardiac hypertrophy and cardiac oxidative stress in chronic renal failure.</abstract><cop>United States</cop><pub>American Heart Association, Inc</pub><pmid>18591458</pmid><doi>10.1161/HYPERTENSIONAHA.107.109645</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0194-911X
ispartof Hypertension (Dallas, Tex. 1979), 2008-08, Vol.52 (2), p.295-300
issn 0194-911X
1524-4563
language eng
recordid cdi_proquest_miscellaneous_69355037
source MEDLINE; American Heart Association Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Journals@Ovid Complete
subjects Analysis of Variance
Animals
Biomarkers - analysis
Blotting, Western
Cardiomegaly - prevention & control
Disease Models, Animal
Immediate-Early Proteins - genetics
Immediate-Early Proteins - metabolism
Male
Mineralocorticoid Receptor Antagonists - pharmacology
Nephrectomy
Oxidative Stress - drug effects
Probability
Protein-Serine-Threonine Kinases - genetics
Protein-Serine-Threonine Kinases - metabolism
Random Allocation
Rats
Rats, Sprague-Dawley
Receptors, Mineralocorticoid - metabolism
Reverse Transcriptase Polymerase Chain Reaction
RNA, Messenger - analysis
Spironolactone - pharmacology
Uremia - physiopathology
Urinalysis
title Mineralocorticoid Receptor Antagonism Attenuates Cardiac Hypertrophy and Prevents Oxidative Stress in Uremic Rats
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-05T18%3A09%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Mineralocorticoid%20Receptor%20Antagonism%20Attenuates%20Cardiac%20Hypertrophy%20and%20Prevents%20Oxidative%20Stress%20in%20Uremic%20Rats&rft.jtitle=Hypertension%20(Dallas,%20Tex.%201979)&rft.au=Michea,%20Luis&rft.date=2008-08&rft.volume=52&rft.issue=2&rft.spage=295&rft.epage=300&rft.pages=295-300&rft.issn=0194-911X&rft.eissn=1524-4563&rft_id=info:doi/10.1161/HYPERTENSIONAHA.107.109645&rft_dat=%3Cproquest_cross%3E69355037%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=69355037&rft_id=info:pmid/18591458&rfr_iscdi=true